Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

February 01, 2005 (Vol. 25, No. 3)

Re-Engineering the Drug Development Pipeline

Implementing ADME-Tox Profiling Earlier in Discovery

  • Fail fast, fail cheap is a common clich in drug development. Studies project that anywhere from 4060% of potential drugs candidates fail in development due to absorption, distribution, metabolism, excretion, and toxicology (ADME-Tox) problems, and that per drug, companies allocate about one-fifth of their R&D budgets to evaluate ADME-Tox ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.